Clear Cell Ovarian Cancer Patients Lacking ARID1A Protein Could Benefit from ENMD-2076 Treatment, Study Reports

Clear Cell Ovarian Cancer Patients Lacking ARID1A Protein Could Benefit from ENMD-2076 Treatment, Study Reports
Results from a Phase 2 clinical trial indicate that an investigational drug by CASI Pharmaceuticals, known as ENMD-2076, may be beneficial for patients with rare clear cell ovarian cancer (CCOC), particularly those who lack the ARID1A protein, a well-recognized indicator of negative prognosis and a potential biomarker. The findings will be presented at the American Society of Clinical Oncology’s 2017 Annual Meeting to be held June 2-6 in Chicago, Illinois. The title of the poster presentation is, “Phase II Clinical and Molecular Trial of Oral ENMD-2076 in Clear Cell Ovarian Cancer (CCOC): A study of the Princess Margaret phase II consortium.” ENMD-2076 is an orally administrated drug that binds and blocks the activity of the Aurora A protein and other tyrosine kinases. These enzymes are essential for normal cell division and proliferation. Exposing cancer cells to ENMD-2076 seeks to impair their growth and promote cell death. This drug also showed promise in inhibiting the growth of new blood vessels required for tumors to proliferate. Following a Phase 1 trial in which ENMD-2076 showed promise in halting various tumor types, including ovarian, breast, liver, renal, and sarcoma, trial researchers from Princess Margaret Phase 2 Consortium explored the effects of ENMD-2076 on patients with recurrent CCOC, who often do not respond to chemotherapy. The Phase 2 trial (NCT01914510) included 40 patients and looked at pro
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *